Evidence map›Paper›PMID 42769710›Full record

ArticleBiomedical optics express2026

Personalized digital pipeline for basal cell carcinoma delineation using hyperspectral imaging.

Paulina Ibek, Alexander Degener, Magne Stridh, Marcus Tegnér, Patrik Edén, Victor Olariu, Malin Malmsjö, Aboma Merdasa

Abstract read
In one paragraph

Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paulina IbekOphthalmology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
Alexander DegenerComputational Science for Health and Environment, Department of Earth and Environmental Sciences, Lund University, Lund, Sweden.
Magne StridhOphthalmology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
Marcus TegnérOphthalmology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
Patrik EdénComputational Science for Health and Environment, Department of Earth and Environmental Sciences, Lund University, Lund, Sweden.
Victor OlariuComputational Science for Health and Environment, Department of Earth and Environmental Sciences, Lund University, Lund, Sweden.
Malin MalmsjöOphthalmology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.ORCID https://orcid.org/0000-0001-9849-9599
Aboma MerdasaOphthalmology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.ORCID https://orcid.org/0000-0002-6298-5672

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Basal cell carcinoma (BCC) is the most common form of skin cancer with the current diagnostic procedures relying on surgical excisions and histopathological analyses. Incomplete removal of the tumor necessitates additional surgery, which is both costly and time-consuming. To address this, non-invasive diagnostic techniques capable of determining the dimensions of skin cancer preoperatively are urgently needed. This work presents the development of an automated diagnostic pipeline for delineating BCC, using hyperspectral imaging (HSI), combined with machine learning (ML). HSI is a non-invasive, high-resolution imaging technique capable of differentiating tissue structures based on their molecular composition. ML is a branch of AI where algorithms learn patterns from data to make predictions without being explicitly programmed. The proposed pipeline is designed to adapt for individual patients, as universal skin cancer characteristic signals are challenging to define. The pipeline predicted tumor sizes with high accuracy, as validated by histopathological measurements in the 21 samples evaluated. The median absolute errors were low (0.25-0.30 mm), meaning that the predicted tumor dimensions were within the clinically accepted safety margins for radical excisions (≤0.4 mm). This work is the first to use unsupervised ML for tumor delineation in BCC using HSI, which enables personalized preoperative assessment and facilitates surgical precision.

Identifiers

PMID42769710
PMCPMC13592271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.